Zhou Yanming, Wu Lupeng, Xu Dong, Wan Tao, Si Xiaoying
Department of Hepatobiliary & Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.
Department of Hepatobiliary & Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.
HPB (Oxford). 2017 Sep;19(9):768-774. doi: 10.1016/j.hpb.2017.05.008. Epub 2017 Jun 20.
Limited data are currently available to address the safety and efficacy of combined resection of the liver and inferior vena cava (IVC) for hepatic malignancies.
A systematic review was performed to identify relevant studies. Pooled individual data were examined for the clinical outcome of combined resection of the liver and IVC for hepatic malignancies.
A total of 258 patients were described in 38 articles eligible for inclusion. Resections were performed for colorectal liver metastasis (CLM) [n = 128 (50%)], intrahepatic cholangiocarcinoma (ICC) [n = 51 (20%)], hepatocellular carcinoma (HCC) [n = 48 (19%)], and other pathologies [n = 31 (11%)]. There were 14 (5%) perioperative deaths. The median survival duration was 34 months, and the 1-, 3- and 5-year overall survival (OS) rate was 79%, 46% and 33%, respectively. The 5-year OS rate was 26% for CLM, 37% for ICC, and 30% for HCC.
Combined resection of the liver and IVC for hepatic malignancies is safe and applicable, and offers acceptable survival outcomes.
目前关于联合切除肝脏和下腔静脉（IVC）治疗肝脏恶性肿瘤的安全性和有效性的数据有限。
进行系统评价以识别相关研究。对汇总的个体数据进行检查，以了解联合切除肝脏和IVC治疗肝脏恶性肿瘤的临床结果。
38篇符合纳入标准的文章共描述了258例患者。手术切除的疾病包括结直肠癌肝转移（CLM）[n = 128例（50%）]、肝内胆管癌（ICC）[n = 51例（20%）]、肝细胞癌（HCC）[n = 48例（19%）]和其他病理类型[n = 31例（11%）]。围手术期死亡14例（5%）。中位生存时间为34个月，1年、3年和5年总生存率（OS）分别为79%、46%和33%。CLM的5年OS率为26%，ICC为37%，HCC为30%。
联合切除肝脏和IVC治疗肝脏恶性肿瘤是安全可行的，并能提供可接受的生存结果。
